益心康泰胶囊联合替罗非班治疗不稳定型心绞痛的临床研究  

Clinical study on Yixin Kangtai Capsules combined with tirofiban in treatment of unstable angina pectoris

作　　者：段娜娜[1] 姬玲粉 宋溢娟 许锦锦[1] 康艳丽[1] 李转珍[2] 赵富利 DUAN Na-na;JI Ling-fen;SONG Yi-juan;XU Jin-jin;KANG Yan-li;LI Zhuan-zhen;ZHAO Fu-li(Department of General Medicine,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China;Department of Internal Medicine-Cardiovascular,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南科技大学第一附属医院全科医学科,河南洛阳471000 [2]河南科技大学第一附属医院心血管内科,河南洛阳471000

出　　处：《现代药物与临床》2022年第12期2776-2780,共5页Drugs & Clinic

基　　金：河南省医学科技攻关计划(联合共建)项目(LHGJ20190576)。

摘　　要：目的 探讨益心康泰胶囊联合替罗非班治疗不稳定型心绞痛的临床疗效。方法 选择2020年6月—2021年12月河南科技大学第一附属医院收治的136例不稳定型心绞痛患者,采用随机数字表法分为对照组(68例)和治疗组(68例)。对照组静脉注射盐酸替罗非班氯化钠注射液,起始30 min滴注速率为0.4μg/(kg·min),输注量完成后,继续以0.1μg/(kg·min)的速率维持滴注,1次/d。在对照组的基础上,治疗组口服益心康泰胶囊,2粒/次,3次/d。两组患者应用药物7 d。观察两组患者临床疗效,比较治疗前后两组患者症状改善时间,心功能指标左室舒张期容积(EDV)、左室射血分数(LVEF)、心脏每搏输出量(SV)和左心室舒张末期压(LVSP),血清白细胞介素-6(IL-6)、血管细胞黏附因子(s VCAM-1)、基质金属蛋白酶-9(MMP-9)和血清内皮素-1(ET-1)水平,及不良反应。结果 治疗后,治疗组总有效率(98.53%)明显高于对照组(85.29%,P<0.05)。治疗后,治疗组患者临床症状改善时间均明显早于对照组(P<0.05)。治疗后,两组患者LVEF、SV指标均明显升高,而LVSP、EDV指标均显著降低(P<0.05);且治疗组LVEF、SV指标均高于对照组,LVSP、EDV指标均低于对照组(P<0.05)。治疗后,两组患者血清IL-6、MMP-9、sVCAM-1、ET-1水平明显下降(P<0.05);且治疗组的IL-6、MMP-9、sVCAM-1、ET-1水平均明显低于对照组(P<0.05)。治疗组不良反应发生率明显低于对照组(P<0.05)。结论 替罗非班与益心康泰胶囊联合治疗不稳定型心绞痛疗效确切,可明显改善心肌缺血状态,减弱炎症反应。Objective To investigate the clinical efficacy of Yixin Kangtai Capsules combined with tirofiban in treatment of unstable angina pectoris. Methods Patients(136 cases) with unstable angina pectoris in the First Affiliated Hospital of Henan University of Science and Technology from June 2020 to December 2021 were divided into control(68 cases) and treatment(68 cases) group according to the random number table method. Patients in the control group were iv administered with Tirofiban Hydrochloride and Sodium Chloride Injection, the initial drip rate of 30 min is 0.4 μg/(kg·min), after the infusion volume was completed, continued to maintain the drip at a rate of 0.1 μg/(kg·min), once daily. Patients in the treatment group po administered with Yixin Kangtai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptom, the cardiac function indexes LVEF, SV, LVSP, and EDV, the levels of serum factor IL-6, MMP-9, sVCAM-1, and ET-1, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group(98.53%) was significantly higher than that of the control group(85.29%, P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was significantly earlier than that in the control group(P < 0.05). After treatment, LVEF and SV indexes were significantly higher in two groups, while LVSP and EDV indexes were significantly decreased(P < 0.05). LVEF and SV indexes in treatment group were higher than those in control group, LVSP and EDV indexes were lower than those in control group(P < 0.05). After treatment, serum levels of IL-6, MMP-9, sVCAM-1 and ET-1 in two groups were significantly decreased(P < 0.05). The levels of IL-6, MMP-9, sVCAM-1and ET-1 in the treatment group were significantly lower than those in the control group(P < 0.05). The incidence of advers

关 键 词：益心康泰胶囊 盐酸替罗非班氯化钠注射液 不稳定型心绞痛 左室舒张期容积 左室射血分数 血管细胞黏附因子 基质金属蛋白酶-9 

分 类 号：R972[医药卫生—药品]